MiniMed

MiniMed, now the Diabetes division of Medtronic, is a global leader in the development of advanced insulin delivery and glucose monitoring technologies. The company is renowned for creating the first "artificial pancreas" system, which integrates insulin pump therapy with continuous glucose monitoring (CGM) to automate insulin dosing. Their current flagship product, the MiniMed 780G system, utilizes proprietary SmartGuard technology to provide real-time adjustments and meal-time corrections for patients with Type 1 diabetes. MiniMed's portfolio also includes the Guardian series of sensors and data management software designed to provide actionable insights for both patients and healthcare providers. Headquartered in Northridge, California, the company remains at the forefront of endocrinology innovation, focusing on reducing the daily burden of diabetes management.